Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (723)	10/18/2002 1:08:10 AM
From: tuck	Read Replies (1) \| Respond to of 1005

Bernard, Introgen licenses technology rights to stuff out of Dr. Roth's lab. So my read of this (the agreement is in the S-1) is that Introgen will be paying M.D. Anderson a royalty for the technology involved, though not the drug itself. Or perhaps bought the rights with a lump sum. The PR is a bit cryptic about that, and of course, the numbers are expunged from the agreement. Could probably be cleared up with a call to Introgen IR dept. I would guess that a patent has been applied for by the researchers, but I'm just not up for a patent search right now. Cheers, Tuck